Preparation method and delivery system of exosome based on dynamic hydrogel
Dynamic hydrogel technology simulates extracellular matrix, improves the function and stability of exosomes, and achieves accurate delivery and long-term sustained release through the control of peptide sustained release, solving the limitation and stability of exosome functions in the prior art Poor sex problem.
Patent Information
- Application Number
- CN202410976611.3
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-20
- Publication Date
- 2024-11-29
- Estimated Expiration
- 2044-07-20
AI Technical Summary
The prior art is difficult to simulate the growth and physiological functions of cells in the physiological environment in vivo, resulting in limited functions of the acquired exosomes and poor exosome stability, making it difficult to achieve accurate drug delivery and long-term sustained release effects.
Dynamic hydrogel technology is used to mix gelatin, acrylic group-modified cyclodextrin and photoinitiator to form a dynamic hydrogel network through photoinitiation crosslinking, simulate the physical properties of extracellular matrix and regulate the cell culture environment. And the sustained release control of exosomes is achieved through the binding of the peptide to the hydrogel.
It improves the functional repair and purity of exosomes, extends the blood sugar control time, realizes accurate delivery and long-term sustained release of exosomes, simplifies operation and improves the therapeutic effect.
Smart Images

Figure SMS_1 
Figure SMS_2 
Figure HDA0004954747440000011
Abstract
Description
Technical Field
[0001] The present invention belongs to the field of biomedical materials and biological preparations, and in particular to a preparation method and delivery system of exosomes based on dynamic hydrogel. Background Art
[0002] Exosomes are a type of cell secretion substance with a small vesicle structure of 50-150nm wrapped by a cell membrane. These tiny vesicles can be released into the extracellular environment through secretion and transmit information between cells. Exosomes have great prospects in clinical applications. Because they are naturally secreted by cells, they have repair and antioxidant effects and do not cause immune responses. At the same time, due to their membrane structure and nanometer size, they can be used as a drug delivery system to cross the blood-brain barrier and have great potential in the treatment of central nervous system diseases.
[0003] At present, most exosomes are obtained by two-dimensional culture on cell culture dishes or suspension culture on the surface of microspheres. It has been reported that hydrogel GelMA is used to culture cells to obtain exosomes, but these cell culture methods are difficult to simulate the growth and physiological functions of cells in the physiological environment in vivo, and the stress changes during cell production. Due to the different mechanical stimulations to cells, the functions of exosomes obtained by this method may be limited, and it is difficult to achieve more accurate drug evaluation effects as a biomarker. In addition, exosomes have poor stability. Exosomes directly injected into the body will be quickly metabolized and cleared, and the therapeutic effect is greatly reduced. Usually, after the exosome solution is injected, it will diffuse rapidly in the body, making it difficult to achieve the purpose of precise treatment. Therefore, the development of new exosome preparation methods, especially functionally enhanced exosomes, is still a problem to be solved. It has been reported in the prior art that exosomes are loaded in hydrogels for in vivo delivery, but the sustained release effect of exosomes in the body is unstable, and it is difficult to formulate a sustained release cycle according to needs. Summary of the invention
[0004] The main purpose of the present invention is to overcome the problems existing in the above-mentioned background technology and provide a method for preparing exosomes based on dynamic hydrogel and a delivery system thereof. One of the purposes of the present application is to provide a method for preparing exosomes, comprising the following steps:
[0005] 1) adding gelatin, cyclodextrin modified with acrylic groups and a photoinitiator into a buffer solution to prepare a precursor solution; mixing cells and the precursor solution, and photoinitiating cross-linking to form a dynamic hydrogel encapsulating the cells;
[0006] 2) After the dynamic hydrogel is placed in a culture medium for culture, the culture medium is collected, and exosomes are obtained by separation and purification.
[0007] After the cells are added to the precursor solution, a three-dimensional hydrogel network is formed by initiating photocrosslinking. The hydrogel network belongs to a dynamic crosslinked hydrogel network, including the host-guest interaction between gelatin and cyclodextrin and the covalent crosslinking between acrylated cyclodextrins. During the cell culture process, the dynamic crosslinked network better simulates the physical properties of the extracellular matrix. By culturing the cells in three dimensions in the dynamic hydrogel, the paracrine of the cells is stimulated, and compared with the exosomes obtained in the conventional two-dimensional cell culture medium, it has a better functional repair effect. In addition, the physicochemical properties such as the dynamic properties and mechanical properties of the dynamic hydrogel can be controlled by the degree of substitution of the acrylic group and the molar ratio between the subject (gelatin) and the guest (cyclodextrin), which can simulate the physiological characteristics of the microenvironment of different tissues in the body (brain, heart, liver, spleen, lungs, kidneys, cartilage, bone, tumors, etc.), and regulate the environment of cell culture, so as to obtain functionally enhanced cell-secreted exosomes and prepare customized exosomes for specific tissue repair or specific disease treatment.
[0008] In some preferred embodiments, the pH of the buffer solution is 7-8, the content of gelatin in the precursor solution is 5-15% (w / v), the content of cyclodextrin modified with acrylic acid group is 5-15% (w / v), and the content of photoinitiator is 0.01-0.5%; in some preferred embodiments, the degree of substitution of acrylic acid in the modified cyclodextrin is 1.0-1.4. Acrylic acid group refers to a group containing acrylic acid and its derivatives.
[0009] In certain preferred embodiments, the photoinitiator initiates photocrosslinking in the blue light range, such as the photoinitiator 2-hydroxy-4′-(2-hydroxyethoxy)-2-methylpropiophenone (I-2959) in the 365 nm band, the photoinitiator 2,4,6-trimethylbenzoylphenylphosphonic acid ethyl ester (TPOL) and phenyl (2,4,6-trimethylbenzoyl) lithium phosphate (LAP) in the 365-405 nm band. In certain embodiments, the photoinitiator can preferably be phenyl (2,4,6-trimethylbenzoyl) phosphate (LAP).
[0010] The method for preparing exosomes of the present application is applicable to exosomes secreted by all types of cells. In some embodiments, the cells are stem cells, such as mesenchymal stem cells, neural stem cells, adipose stem cells, umbilical cord blood stem cells and bone marrow stem cells; in some embodiments, the culture medium is a serum-free culture medium; in some embodiments, the dynamic hydrogel is first cultured in a conventional culture medium and then cultured in a serum-free culture medium. In some embodiments, the exosomes prepared by the method can be used for a) preparing a pharmaceutical composition for treating diabetes; or b) preparing a preparation or composition that has the effects of lowering blood sugar, repairing insulin cells, increasing insulin expression, and improving insulin resistance.
[0011] Another object of the present application is to provide an application of a dynamic hydrogel in the preparation of exosomes, wherein the dynamic hydrogel comprises a dynamic cross-linked network formed by gelatin and cyclodextrin modified with acrylic groups through host-guest interactions, and the modified cyclodextrin is covalently cross-linked by light initiation.
[0012] Another object of the present application is to provide a delivery system for exosomes, the delivery system comprising a dynamic hydrogel formed by host-guest interaction and covalent crosslinking of gelatin and cyclodextrin modified with acrylic groups, wherein the cyclodextrin is covalently crosslinked by light initiation. In certain embodiments, the delivery system further comprises a polypeptide connected to the dynamic hydrogel that can bind to the exosomes. By connecting the polypeptide in the dynamic hydrogel, a controlled sustained release period can be provided to the exosomes.
[0013] In certain embodiments, the release cycle of exosomes can be regulated by regulating the molar ratio of the polypeptide and exosomes introduced into the dynamic hydrogel.
[0014] In some embodiments, the polypeptide is connected to the hydrogel via N-hydroxysuccinimide (NHS) modified by acrylic groups. The amino groups on the polypeptide undergo click chemistry reaction with the modified NHS, and the modified NHS is covalently cross-linked with cyclodextrin modified by acrylic groups through a photo-induced cross-linking reaction. By introducing polypeptide chains that can bind to exosomes into the dynamic hydrogel, not only the sustained release effect of exosomes is greatly enhanced, but also the precise delivery of exosomes is achieved, avoiding their diffusion in the body and being cleared, which affects the delivery effect.
[0015] The polypeptide peptide chain has a wide range of choices and can be optimized for different delivery parts or the function of delivering exosomes, and has a wide range of uses. For example, in some embodiments, the polypeptide includes but is not limited to CP05 and its derivative peptides, CP06 and its derivative peptides, CP07 peptides and its derivative peptides, and integrin-related binding peptides. In some preferred embodiments, the polypeptide peptide chain is additionally connected with a glycine (G) as the first position of the N-terminus, that is, a glycine is added before the N-terminus of the polypeptide peptide segment.
[0016] Another object of the present application is to provide a method for preparing an exosome delivery system, comprising:
[0017] 1) mixing gelatin and cyclodextrin modified with acrylic groups in a buffer solution, adding a photoinitiator, and preparing a precursor solution;
[0018] 2) The precursor solution and the exosome solution are mixed and light is induced to cross-link to form a hydrogel.
[0019] In certain embodiments, the method further comprises pre-mixing N-hydroxysuccinimide modified with an acrylic group with a polypeptide at 4° C. as a supplementing solution, then adding the supplementing solution to the exosome solution and mixing to obtain an exosome mixed solution, which is then added to the precursor solution and irradiated with light to form a sustained-release dynamic hydrogel; wherein the polypeptide can bind to the exosomes.
[0020] In certain embodiments, the polypeptide includes but is not limited to CP05 and its derivative peptides, CP06 and its derivative peptides, CP07 peptide and its derivative peptides, and integrin-related binding peptides. In certain preferred embodiments, the polypeptide peptide chain is additionally connected with a glycine (G) as the first position at the N-terminus. In certain embodiments, the polypeptide peptide chain is PPFLMLLKGSTR or PPFLMLFKSPKR or PPFLMLFKSPKG; in certain preferred embodiments, the molar ratio of the modified NHS to the polypeptide ranges from (5:1) to (1:5), for example, optionally 5:1, 4:1, 3:1, 2:1, 1:1, 1:2, 1:3, 1:4 or 1:5, and the concentration of the modified NHS or polypeptide in the supplement is 0.04-1.5 mg / mL.
[0021] Another object of the present application is to provide an application of a dynamic hydrogel system in the preparation and delivery of exosomes. Specifically, exosomes are obtained by using dynamic hydrogel three-dimensional culture cells, and then the hydrogel system is used to deliver exosomes.
[0022] In certain embodiments, the dynamic hydrogel system is formed by photo-crosslinking initiated by a precursor solution, wherein the precursor solution includes gelatin and cyclodextrin modified with acrylic groups, and the dynamic hydrogel is formed by the host-guest interaction between the aromatic residues on the gelatin and the cyclodextrin modified with acrylic acid, and the carbon-carbon double bonds on the acrylic acid residues are photo-crosslinked. The dynamic hydrogel can mimic the environment of the extracellular matrix, and the cells can be cultured three-dimensionally using the hydrogel to obtain functionally enhanced exosomes. Subsequently, the exosomes are encapsulated by the hydrogel and injected into the delivery part, so that precise sustained-release drug delivery can be achieved at the treatment site.
[0023] Another object of the present application is to provide an exosome kit, the kit comprising a precursor solution, the precursor solution comprising gelatin, acrylic acid-modified cyclodextrin, and a photoinitiator; after the precursor solution is mixed with cells, light is induced to cross-link to prepare a dynamic hydrogel for preparing functionally enhanced exosomes. After the exosomes are obtained, the precursor solution is added, and light is induced to cross-link to form a dynamic hydrogel, which is used for injection into a specific part for sustained release delivery.
[0024] In a further step, the kit includes a supplementing solution, which includes a polypeptide that can bind to exosomes and N-hydroxysuccinimide modified with an acrylic group. In certain embodiments, the polypeptide includes but is not limited to CP05 and its derivative peptides, CP06 and its derivative peptides, CP07 peptide and its derivative peptides, and integrin-related binding peptides. In certain preferred embodiments, the polypeptide peptide chain is additionally connected with a glycine (G) as the first position at the N-terminus.
[0025] In some embodiments, after obtaining the exosomes, a supplementing liquid is added to the exosomes and mixed, and then a precursor solution is added, and light-induced cross-linking forms a dynamic hydrogel, which is used for injection into a specific part for sustained release delivery, and the release period can reach more than 14 days. In some embodiments, the release period of the exosome delivery can be regulated by adjusting the ratio of the supplementing liquid and the exosomes. The kit uses a precursor solution to achieve the preparation of functionally enhanced exosomes and periodically controlled sustained release delivery, which has good therapeutic effects and is convenient and efficient to use.
[0026] The beneficial technical effects of this application are as follows:
[0027] 1. Dynamic hydrogels can change the dynamic and mechanical properties of dynamic hydrogels by adjusting the components, and can simulate the physiological characteristics of different tissue microenvironments in the body, thereby regulating the composition of exosomes secreted by cultured cells and preparing customized exosomes for specific tissue repair or specific disease treatment. Exosomes obtained by culture in mesenchymal stem cells are more than 3 times more effective in lowering blood sugar than exosomes cultured in two dimensions by traditional methods. Combined with a sustained-release dynamic gel delivery system, the blood sugar control time is extended to more than 14 days.
[0028] 2. The process of extracting the exosomes obtained by the preparation method of the present application by differential centrifugation is also more efficient than the extraction method of two-dimensional or traditional three-dimensional culture. Because the cultured cells are encapsulated in the dynamic hydrogel, the speed and amount of larger molecules such as cell fragments, apoptotic bodies and protein aggregates that penetrate into the cell culture medium are smaller than those of exosomes. Under similar differential centrifugation operations, the exosomes obtained by the method of the present application have higher purity.
[0029] 3. Simple operation: A hydrogel system can be used to achieve the dual functions of exosome acquisition and delivery, simplifying the types of reagents and making the operation easy to use.
[0030] 4. The delivery cycle is controllable: Depending on the treatment cycle, different exosome release curves can be achieved by changing the concentration of the supplement solution, thereby achieving the effect of long-term treatment with a single dose.
[0031] 5. Precision: Hydrogel can be injected to cover irregular wounds, or directly injected into the lesion to achieve precise treatment. BRIEF DESCRIPTION OF THE DRAWINGS
[0032] Figure 1 Scanning electron microscopy results of exosomes prepared in Example 1 (left), and nanoparticle tracking analysis (NTA)
[0033] To characterize the distribution of exosomes (right).
[0034] Figure 2 Fluorescence intensity of exosomes encapsulated in hydrogel changes over time.
[0035] Figure 3 Schematic diagram of the injectability of exosome-encapsulated sustained-release dynamic hydrogel.
[0036] Figure 4 The cell viability was measured after 72 hours of incubation with normal exosomes and function-enhanced exosomes in damaged β cells.
[0037] Figure 5 The left figure shows the changes in insulin expression in rats after injection of encapsulated exosome hydrogels, and the right figure shows the quantitative data of insulin expression fluorescence intensity.
[0038] Figure 6 Western blot (WB) results of insulin expression were normalized to quantitative data (the concentration of exosomes was 100 μg / mL).
[0039] Figure 7 The phosphorylation results of insulin receptor substrate IRS-1 were normalized to quantitative data (the concentration of exosomes was 100 μg / mL).
[0040] Figure 8 Changes of blood glucose in diabetic rats after injection of exosomes.
[0041] Fig. 9 IPGTT tested on day 7 after diabetic rats were injected with exosome-encapsulated hydrogel.
[0042] Fig.10 IPGTT results of diabetic model rats tested on the 14th day after injection of encapsulated exosome hydrogel. Fig.11 After MSC cells obtained by different methods were co-cultured with damaged β cells for three days, CCK-8 was used to test the cell viability results. DETAILED DESCRIPTION
[0043] Some embodiments of the present invention are described in detail below. It should be emphasized that the following embodiments are merely exemplary and should not be considered as limiting the scope of the present invention and its application.
[0044] The functionally enhanced exosomes described in this application refer to exosomes that have enhanced ability to regulate cell status and function, such as improving cell viability, enhancing cell repair ability, etc., compared with exosomes obtained by conventional two-dimensional and three-dimensional culture methods. The functional enhancement may also refer to lowering blood sugar, increasing insulin expression, improving insulin resistance, reducing inflammatory response, promoting angiogenesis, inhibiting fibrosis, enhancing immune function, etc.
[0045] Unless otherwise specified, all reagents used in this application are commercially available products.
[0046] Example 1
[0047] 1.1 Preparation of standard dynamic hydrogels
[0048] Synthesis of acrylic acid-modified β-cyclodextrin (AC-β-CD): Add 10g β-CD and 7mL triethylamine to 150mL dimethylformamide, and cool the mixture to 0°C. Add 5mL acrylic acid to the mixture and stir continuously at 0°C for 12 hours. Then, filter the mixture, remove the precipitate, and obtain a clear solution. After rotary evaporation and concentration, slowly pour the concentrated solution into 10 times the volume of acetone solution to obtain a precipitated modified β-CD crude product. The degree of acryl substitution of modified β-CD is calculated by nuclear magnetic resonance. This method is used to prepare modified β-CD with a degree of substitution between 1.0 and 1.4 by changing the addition ratio of cyclodextrin and acrylic acid. In this embodiment, Ac-β-CD with degrees of substitution of 1.0, 1.1, 1.2, 1.3 and 1.4 are synthesized. Adjusting the degree of substitution of modified cyclodextrin with acrylic acid can adjust the mechanical properties of dynamic hydrogels. Within this range, the storage modulus of the hydrogel is between 0.8 and 3 kPa. When the degree of substitution increases, the storage modulus increases accordingly, thereby matching the growth environment of different cells and optimizing the function of cultured cells. In addition, the mechanical strength of the hydrogel also affects the release rate of the exosomes coated therein.
[0049] Preparation of precursor solution of standard dynamic hydrogel: The main components of the precursor solution of hydrogel are gelatin and modified β-CD, which are dissolved in PBS after adding photoinitiator (phenyl (2,4,6-trimethylbenzoyl) lithium phosphate, LAP, TCI), and the precursor solution forms dynamic hydrogel under light conditions. In this embodiment, precursor solutions of gelatin and modified CD in different proportions are prepared, wherein the gelatin in the precursor solution ranges from 5% w / v to 10% w / v, the modified β-CD is 8% w / v to 15% w / v, and the LAP is 0.01-0.5% w / v.
[0050] According to the test results, when the ratio of the precursor solution is within the above range, the formed dynamic hydrogel has good injectability and adhesion; the hydrogel has moderate strength, is suitable for the growth of bone marrow mesenchymal stem cells, is non-cytotoxic and degradable.
[0051] Human tissue has the dynamic property of stress relaxation, and most traditional hydrogel materials do not have this dynamic property. Dynamic hydrogels can highly simulate the extracellular matrix in which human cells are located. Their highly dynamic three-dimensional network structure not only has the characteristics of cell adaptation, but can also adjust its own network structure as cells grow. In this application, the inventors found that dynamic hydrogels can also provide mechanical stimulation to cells that traditional hydrogels cannot provide, so as to promote cell proliferation and regulate cell secretion function, thereby increasing the production of exosomes and obtaining customized exosomes with enhanced functions.
[0052] Cells in the body are always stimulated by various forms of mechanical signals (such as mechanical properties such as rigidity and stress relaxation of the extracellular matrix). The dynamic hydrogel of this application has adjustable stress relaxation and mechanical properties, which can give cells different mechanical environments. Cells can sense these mechanical stimuli and transduce mechanical stimulation signals into biochemical signals, thereby activating a series of responses in the cells, ultimately affecting functions such as cell differentiation and migration. Unlike traditional hydrogel three-dimensional culture, which can only provide support and protection for cells, this application found that dynamic hydrogel can provide a large number of mechanical stimulation signals to promote the secretion of exosomes. There are currently many physical and chemical stimulation methods to increase the secretion rate and yield of exosomes. Studies have shown that physical stimulation can lead to a significant increase in exosome production, especially mechanical mechanical stimulation, which can increase the secretion value by about 150 times compared with traditional two-dimensional culture. However, excessive mechanical stimulation can cause excessive cell pressure and affect cell growth. The dynamic glue developed in this project has adjustable stress relaxation and mechanical properties, which can simulate the mechanical characteristics of the extracellular matrix in the human body, provide cells with appropriate mechanical stimulation, and maintain high cell vitality while promoting the generation of cell exosomes.
[0053] In addition, the mechanical properties of dynamic hydrogels can be adjusted over a wide range by changing host-guest interactions or covalent cross-linking. Therefore, by adjusting the component ratio of dynamic hydrogels, the microenvironment characteristics of different tissues in the body can be accurately simulated, the matrix stiffness and mechanical properties of the native microenvironment of different cells in the body can be matched, and mechanical stimulation similar to the native microenvironment can be provided to different cells. A bionic three-dimensional culture model can be constructed in vitro to obtain customized exosomes with different functions to meet the treatment needs of different diseases.
[0054] Based on the above experiments, the inventors selected a standard dynamic hydrogel formula ratio for subsequent testing (standard dynamic hydrogel), which is: 8% w / v gelatin, 10% w / v modified β-CD, using 0.05% w / v LAP, dissolved in phosphate buffer (PBS) at 37°C, and then exposed to 405nm visible light for 5 minutes to obtain a standard dynamic hydrogel with a wavelength power of 5-20w.
[0055] 1.2 Obtaining exosomes from cells cultured in dynamic hydrogels
[0056] Standard dynamic hydrogels were used to encapsulate cells. Primary bone marrow mesenchymal stem cells (MSCs) extracted from rats at 2 weeks of age were used in the test experiment. MSCs were first mixed with the precursor solution of the standard dynamic hydrogel. The concentration in each 50 μl of the hydrogel precursor solution was 5×10 5 The cell-encapsulated hydrogel was obtained by using the photocuring method described in 1.1.
[0057] The cell-encapsulated hydrogel was cultured in a culture medium using complete culture medium (α-MEM culture medium (Gibco) supplemented with 16.7% fetal bovine serum (Sigma-Aldrich) and 1% L-glutamine (Gibco) and 1% penicillin-streptomycin solution (Gibco)) for two days. After the MSCs were fully activated, they were cultured in a serum-free culture medium (Lonza's X-Vivo20 was used in the test experiment) for 24 hours. The serum-free culture medium was collected and three-dimensional cultured exosomes were obtained by differential centrifugation. The differential centrifugation method was set to collect the supernatant at 500g for 5 minutes at 4°C, the supernatant was collected at 2000g for 5 minutes, the supernatant was collected at 10000g for 30 minutes, and the precipitate was collected at 100000g for 70 minutes. The precipitate was the desired exosome. The experimental results of characterizing exosomes by electron microscopy and nanoparticle tracking analysis (NTA) are shown in Figure 1 shown.
[0058] Comparison of exosomes prepared by dynamic hydrogels and other methods
[0059] This experiment investigated the effects of conventional two-dimensional culture, GelMA culture, and dynamic hydrogel culture on the acquisition of exosomes from mesenchymal stem cells. In the GelMA hydrogel, the solid content of GelMA was 8%, and MSCs were encapsulated with GelMA at a density of 500,000 cells per 50 μL of gel. α-MEM complete medium (α-MEM + 20% fetal bovine serum + 1% streptomycin / penicillin + 1% L-glutamine) was used to obtain exosomes by differential centrifugation.
[0060] The number of bone marrow mesenchymal stem cells encapsulated by the standard dynamic hydrogel was consistent with that of the bone marrow mesenchymal stem cells cultured in two dimensions, and the differential centrifugation method was used to obtain exosomes. The culture medium formula for conventional two-dimensional culture was: α-MEM medium (Gibco) supplemented with 20% fetal bovine serum (Sigma-Aldrich), 1% L-glutamine (Gibco), and 1% penicillin-streptomycin solution (Gibco).
[0061] The BCA method was used to determine the protein content of the exosomes obtained by the above method, and the number of exosome particles was detected using the Nanoj particle tracer analyzer NTA.
[0062] BCA detection: The BCA protein quantification kit of Biotech was used for detection, in which the concentration gradient curve was in the range of 0.1-1 mg / mL, the R of the concentration gradient curve was less than 0.99, and the data were measured in three replicate wells for each protein sample.
[0063] For NTA detection, the control exosomes and the enhanced exosomes were first adjusted to the same concentration, then diluted 1000 times, vortexed to mix thoroughly, and then injected into the sample pool. When only 10-20 particles were observed in one viewing angle in the observation camera, the measurement was started. The instrument was Nanosight NS300, and the test was repeated three times.
[0064] The results showed that, through the BCA method, at the same concentrated volume, the protein concentration of the exosomes prepared by the dynamic hydrogel was about 2.5 times and about 1.5 times that of the exosomes obtained by the two-dimensional culture method and the GelMA culture method, respectively. It was also found in the NTA test that within the same confidence interval, the exosomes obtained by the dynamic hydrogel adjusted to the same concentration had more particles, and in the drawn image, the proportion of particles within 90-130nm was higher. The three-dimensional polymer network of the dynamic hydrogel will limit the release of larger impurities such as cell fragments from the dynamic gel, while exosomes with a size of 50-150nm will be more easily released from it, so the purity of the exosomes obtained by subsequent separation will be higher than that of other cells directly or partially contacting the culture medium. From the above experiments, it can be concluded that the exosomes obtained by dynamic hydrogels have not only higher yields but also higher purity than those obtained by other two-dimensional and three-dimensional methods.
[0065] Example 2
[0066] 2.1 Preparation method of sustained-release dynamic hydrogel
[0067] Preparation of Methacrylic Acid Modified N-Hydroxysuccinimide (MMA-NHS)
[0068] Dissolve 86 mg of methacrylic acid (MMA) and 115 mg of N-hydroxysuccinimide (NHS) in 10 mL of tetrahydrofuran (THF) at 5°C, add 206 mg of N,N'-dicyclohexylcarbodiimide (DCC), stir continuously, and react for 24 hours. Vacuum filter the reaction solution to remove the precipitate. Add ten times the volume of ice ether to the solution, and vacuum filter to collect the precipitate. Dissolve the precipitate with THF, add ice ether for recrystallization, and repeat this step 3 times. The collected product is dried in a vacuum oven until solid.
[0069] MMA-NHS can use its NHS group to react with the amino group on the polypeptide to form MMA-NHS-polypeptide by click chemistry, and then the carbon-carbon double bond provided by the MMA group and the carbon-carbon double bond on the acrylic acid-modified β-CD can undergo visible light-induced free radical polymerization. Gelatin, modified β-CD, and photoinitiator are added to a buffer solution to prepare a precursor solution. After adding MMA-NHS-polypeptide, a sustained-release dynamic hydrogel containing the polypeptide can be formed by irradiation.
[0070] Synthesis of peptides
[0071] Add 1.0 g of 2-chlorotriphenylphosphine resin (1 mmol of chlorine per gram) to a solid phase synthesis tube and swell with 10 mL of dry dichloromethane (DCM) for 1 hour. After removing the solvent, add 3 equivalents of Fmoc-Arg(Pbf)-OH (3.0 mmol), 6 equivalents of N,N-diisopropylethylamine (DIPEA, 6.0 mmol) and 10 mL of dry N,N-dimethylformamide (DMF) to the resin. The resulting solution containing the resin is reacted at room temperature for 2 hours. After the reaction is completed, the resin is rinsed alternately with DMF three times. In order to proceed to the next step of the amino acid coupling reaction, the resin is treated with DMF (10 mL) containing 20% piperidine at room temperature for 15 minutes to remove the Fmoc group. Then, Fmoc-lys-OH (1 equivalent) was coupled to the resin by adding benzotriazole-N,N,N',N'-tetramethyluronium hexafluorophosphate (HBTU, 3 equivalents), 1-hydroxybenzotriazole (HOBT, 3 equivalents) and DIPEA (6 equivalents) in DMF for 1 hour. The above steps were repeated until the last proline (P) was connected, and an additional glycine (G) was connected as the first N-terminal. After washing, the resin was treated with 95% trifluoroacetic acid (TFA), 2.5% triisopropylsilane (TIPS) and 2.5% water for 2 hours to achieve peptide cleavage and remove side chain protecting groups. After filtration, the peptide was precipitated with a large amount of cold water and the crude product was obtained after centrifugation. Finally, the crude product was purified by reversed-phase high-performance liquid chromatography and the correct synthesis was checked by quadrupole time-of-flight mass spectrometry.
[0072] Through the above experimental method, the inventor synthesized integrin-related binding peptides (peptide segments are PPFLMLLKGSTR / PPFLMLFKSPKR / PPFLMLFKSPKG, which are three corresponding peptide sequences on humans / rat / mouse, respectively. The second rat-related peptide segment is used in the following text). This sequence belongs to a segment in the globular domain LG3 of laminin α3. This segment achieves cell adhesion, diffusion and binding with integrin α3β1. There are integrin binding sites on the membrane structure of exosomes, so anchoring can be achieved. At the same time, due to the presence of multiple amino groups on the side groups of the peptide chain, in order to make the click reaction occur at the head end of the polypeptide as much as possible, a minimum steric hindrance amino acid, glycine G, was added before the peptide segment.
[0073] Preparation of replenishing solution and sustained-release dynamic hydrogel :
[0074] The dynamic hydrogel formulation of this embodiment is shown in Table 1.
[0075] Table 1 Standard dynamic hydrogel and sustained-release dynamic hydrogel formula (1 mL system):
[0076]
[0077] This experiment investigated the effect of changing the final concentration of MMA-NHS and peptide in the supplement solution on the sustained release effect. In this group of experiments, the final concentration of exosomes in the system was controlled to be 1 mg / mL. The final concentration of MMA-NHS in the control group was 0.12 mg / mL, and the final concentration of the peptide solution was 1 mg / mL (making the molar ratio of MMA-NHS to peptide 1:1). The proportions of the experimental groups are shown in Table 2 below.
[0078] Table 2
[0079]
[0080] The four experimental groups were combined with the control group. After the exosomes were inserted into the DIO fluorescent probe, the sustained release of the exosomes in a four-week period was observed under a laser confocal microscope. Compared with the control group, the sustained release effects of ratio one and ratio two were not as good as the control group, and the effects of ratio three and ratio four were slightly better than the control group, but the effects were not obvious.
[0081] Changing the final concentration of exosomes: In this group of experiments, the molar concentration of MMA-NHS: polypeptide in the control supplement solution was 1:1. The final concentration of exosomes in the control group was 1 mg / mL. The final concentrations of exosomes in the experimental groups were: 0.25 mg / mL, 0.5 mg / mL, 1.5 mg / mL, and 2 mg / mL. The four experimental groups were put together with the control group. After the exosomes were inserted into the DIO fluorescent probe, the sustained release of exosomes in a two-week period was observed under a laser confocal microscope. Compared with the control group, the sustained release rate of the low-concentration exosome group was similar to that of the control group, while the high-concentration exosome group had a burst release of exosomes, and the early release was too fast, indicating that at this supplement solution concentration, the final concentration of the exosome solution was more appropriate at 1-1.5 mg / mL.
[0082] The experimental results show that when the ratio of MMS-NHS to polypeptide is greater than 1:1, the release period is longer (more than 10 days). When the ratio is less than 1:1, the release rate of exosomes increases, but is still less than the standard dynamic hydrogel without added polypeptide (5 days). The concentration of MMS-NHS in this example is 0.04-1.5 mg / mL.
[0083] In the subsequent effect verification examples, NHS and polypeptide were mixed in an equal molar concentration ratio, so that NHS reacted with the N-terminus of the polypeptide and preserved the complete chain segment to function, thereby constructing a sustained-release dynamic hydrogel. By adjusting the molar ratio of NHS to polypeptide and the ratio of exosome addition, a controllable sustained-release cycle can be achieved.
[0084] Preparation of sustained-release functionally enhanced exosomes by encapsulating exosomes in hydrogel
[0085] The supplement solution (wherein the content of modified NHS and peptides was 1 mg / ml) was mixed with the exosome solution (2.5 mg / ml) to prepare an exosome mixed solution, and the volume ratio of the supplement solution to the exosome solution was 1:3. The exosome mixed solution was placed at room temperature for 2 hours, and then mixed at 37°C according to the volume ratio of the precursor solution: exosome mixed solution of 3:2, and then blue light was triggered for 5 minutes to form a sustained-release dynamic hydrogel.
[0086] 2.2 Sustained release effect test of sustained release dynamic hydrogel
[0087] After the functional enhanced exosomes were extracted according to the method of Example 1, 3,3'-dioctadecyloxacarbocyanine chlorate (DIO, cell membrane green fluorescent probe, Bio-Tech) was used to incubate the exosomes at 37°C for 20 minutes, and then centrifuged at 4°C and 100,000 g for 70 minutes using a high-speed centrifuge to obtain the precipitate. The exosomes after the probes were inserted were encapsulated using the encapsulation method described in 2.1, and the fluorescence intensity of different days was recorded using an LSM-880 laser confocal microscope (see Figure 2). The standard dynamic hydrogel is obtained by directly mixing the precursor solution and the exosome solution and initiating a photocrosslinking reaction. The sustained-release dynamic hydrogel is obtained by mixing the precursor solution and the supplement solution and initiating crosslinking. The fluorescence quantitative statistical data is shown below the fluorescence graph. It can be found that the exosomes of the standard dynamic hydrogel have been released within 5 days, while the sustained-release dynamic hydrogel releases for two weeks to reach the same fluorescence intensity.
[0088] The supplement solution was mixed with the exosome solution to prepare an exosome mixture, and then the precursor solution was added to prepare a dynamic hydrogel. The molar ratio of polypeptide to exosome in the exosome mixture was tested at 3:1, 2:1, 1:1, 1:2, and 1:3 (the final concentration of exosomes was 1 mg / ml). The experimental results showed that the mixtures of the above ratios could produce a sustained release effect. When the molar ratio of polypeptide to exosome was 1:3, the sustained release period was about 14 days. By increasing the proportion of polypeptide, the sustained release period was gradually extended. When the ratio was less than 1:1, the extension of the sustained release period was gradually not obvious. The exosome mixture was placed at room temperature for 2 hours, and the precursor solution: exosome mixture was mixed at 37°C with a volume ratio of 4:1, 3:1, 2:1, 3:2, and 1:1, respectively, and blue light was triggered for 5 minutes to form a sustained-release dynamic hydrogel. The experimental results showed that when the ratio of the exosome mixture was certain, the ratio of the precursor solution to the exosome mixture was greater than 4:1, which reduced the release rate of the dynamic hydrogel.
[0089] Conventional hydrogel drug delivery systems have a gel pore size that is much larger than the diameter of exosomes. After implantation into the human body, exosomes are rapidly released in large quantities due to the diffusion of concentration gradients and rapid material exchange with the surrounding environment in the body. The dynamic hydrogel drug delivery system of the present application is implanted with polypeptides to anchor the exosomes, allowing the exosomes to be slowly released as the hydrogel swells and degrades, thereby achieving a long-term therapeutic effect.
[0090] Figure 3 The injectability of the sustained-release dynamic hydrogel encapsulating exosomes is shown. The hydrogel was dyed pink with rhodamine and loaded into a syringe, which can be ejected through a one-ml injection needle. The shape can be customized and adhesion can be achieved. This experiment shows that the sustained-release dynamic hydrogel encapsulating exosomes can achieve the purpose of local injection and precise treatment.
[0091] Example 3
[0092] This example investigates the enhanced function of exosomes prepared by dynamic hydrogels in cells.
[0093] 3.1 Experimental methods
[0094] This experiment used the functionally enhanced exosomes obtained by 3D culture of primary bone marrow mesenchymal stem cells in hydrogel of Example 1, and the exosomes obtained by conventional 2D culture of bone marrow mesenchymal stem cells MSC as the control group. The culture medium formula of the control group was: α-MEM culture medium (Gibco) supplemented with 20% fetal bovine serum (Sigma-Aldrich), 1% L-glutamine (Gibco) and 1% penicillin-streptomycin solution (Gibco). The PBS solution containing exosomes was added to the cell culture medium and incubated. The functionally enhanced exosomes prepared by the method of Example 1 were used to test the therapeutic effect in the cells. The concentrations of treatment for the control group and the functionally enhanced exosome group were 10, 25 μg / mL, 50 μg / mL, 100 μg / mL, and 125 μg / mL.
[0095] Injury protocol for pancreatic β cells (Oricell, INS-1 rat insulinoma cell line): conventional culture medium (RPMI-1640 culture medium (Gibco) supplemented with 10% fetal bovine serum (Sigma-Aldrich) and 1% penicillin-streptomycin solution (Gibco)) mixed with 10 μmol / L concentration of streptozotocin (STZ, Beyotime Biotechnology, a common modeling drug for type 2 diabetes) was used for 8 hours. Under this condition, the cell proliferation ability decreased by 25%, and the reactive oxygen species (ROS) increased by 28%, simulating the damaged state of pancreatic β cells in the late stage of type 2 diabetes.
[0096] CCK-8 test: Cell Counting Kit-8 (CCK-8, Bio-Tech Bio) was used to detect the cell viability of the two groups after pancreatic β-cell injury and treatment. Detection steps: 10 μL of CCK-8 solution was added to each well of the damaged β-cells and the treated β-cells, and the cells were incubated in the incubator for 45 minutes. The absorbance was measured at 450 nm. The cell proliferation effects of different experimental groups were compared by comparing the absorbance. The higher the absorbance, the more cells there are, which means that the number of cells proliferated in the same period of time, that is, the cell proliferation rate was fast.
[0097] 3) ROS detection: Use the reactive oxygen species detection kit of Biyuntian Biotechnology to detect the damaged state of the pancreatic β cell line. Detection steps: Use 10μmol / L DCFH-DA diluted in serum-free culture medium (a probe that has no fluorescence itself. After entering the cell, it can be hydrolyzed by esterase in the cell to generate DCFH. DCFH cannot penetrate the cell membrane, and the reactive oxygen species in the cell can oxidize the non-fluorescent DCFH to generate fluorescent DCF. The level of reactive oxygen species in the cell can be known by detecting the intensity of green fluorescence.) Replace the culture medium of the treated pancreatic β cells, incubate in a 37°C cell culture incubator for 20 minutes, wash the cells three times with serum-free culture medium to remove the DCFH-DA that has not entered the cells, and use the Invitrogen EVOS M5000 fluorescence imaging system to observe the intensity of green fluorescence.
[0098] 4) Immunofluorescence staining: The pancreatic β cells were fixed with 4% paraformaldehyde solution at 4°C overnight, treated with 0.25% Triton-X for 25 minutes to permeabilize the cells, and blocked with PBS containing 3% bovine serum albumin and 0.1% Tween 20 for 1 hour. Insulin monoclonal antibody was used as the primary antibody (Proteintech, 1:500), mouse antibody with green fluorescence was used as the secondary antibody (Proteintech, 1:500), 4',6-diamidino-2-phenylindole (DAPI, Biyuntian Biological, 1:500) was used to stain the nucleus, and phalloidin was used to stain the cytoskeleton (Cytoskeleton, 1:500), and the LSM-880 laser confocal microscope was used for observation and photography. This example also performed immunofluorescence staining on Glut2 / Glut4, a key marker of pancreatic β cells, to investigate the repair effect of exosomes on cells.
[0099] 5) Western Blot experiment: Pancreatic β cells were lysed on ice for 30 minutes using RIPA lysis buffer at 100 μL / well, centrifuged at 12000 rpm for 10 minutes, and the supernatant was taken. After the protein concentration was determined by the BCA method, the protein loading buffer was added and the sample was prepared in a 95°C water bath for 10 minutes. Then, the SDS-PAGE gel was prepared, and the protein sample and marker were added to the loading tank respectively. The electrophoresis was performed at 80V for 20 minutes and 120V for 1 hour. The bands on the gel were transferred to the PVDF membrane using the semi-dry transfer method, and blocked with the Ya enzyme fast blocking solution for 20 minutes, and then incubated with the corresponding primary antibody at 4 degrees overnight, and then incubated with the corresponding secondary antibody at room temperature for 1 hour, and developed using the Bio-RAD developer.
[0100] This example uses STZ-induced damaged β cells to investigate the therapeutic effect of exosomes on damaged cells. After adding different concentrations of normal exosomes (control group) and functionally enhanced exosomes to damaged β cells for 72 hours, the cell viability is tested using the CCK-8 method. Figure 4 The experimental data of the 100 μg / mL exosome group are shown; this example examines the immunofluorescence staining data of insulin, where Figure 5 The intensity of green in the left picture reflects the amount of insulin expression, and the right picture is the quantitative data of the fluorescence intensity of insulin expression; through immunofluorescence staining experiments, it was observed that Glut2 / Glut4, the key markers of pancreatic β cells, also increased significantly after exosome treatment. Figure 6 It is the normalized quantitative statistical data of Western blot results. It can be found that the functionally enhanced exosomes prepared in this application can improve the cell viability of damaged β cells at concentrations of 50μg / mL and 100μg / mL as measured by CCK-8, and through immunofluorescence staining and Western Blot experiments, it is concluded that the functionally enhanced exosomes have better therapeutic effects than the control exosomes extracted from two-dimensional cell culture, including a higher increase in insulin expression ( Figure 6 ), the insulin receptor substrate IRS-1 is more phosphorylated ( Figure 7 ) and the protein expression of glucose transport receptor proteins Glut2 and Glut4. IRS is a substrate of pancreatic receptor tyrosine kinase that can be activated. It has more than a dozen tyrosine residues that can be phosphorylated. Tyrosine-phosphorylated IRS will expose binding sites for many signal transduction partners to bind. Insulin resistance inhibits the tyrosine phosphorylation of IRS, affects the signal transduction effect of insulin, and leads to the occurrence of diabetes. Therefore, the increase in tyrosine phosphorylation of IRS indicates the restoration of cellular insulin sensitivity, effectively improves insulin resistance, and restores cell function. It shows that the function-enhanced exosomes of the present application not only unilaterally stimulate the expression of insulin, but also achieves the inhibition of apoptosis and functional repair of pancreatic islet cells, showing that the exosomes obtained by the three-dimensional culture of hydrogels in the present application have more comprehensive therapeutic capabilities.
[0101] Example 4
[0102] This example investigates the therapeutic effects of functionally enhanced exosomes prepared and delivered by dynamic hydrogels in animal experiments.
[0103] This example investigates the effect of applying the functionally enhanced exosomes obtained by the hydrogel system prepared by the method of Example 2 and the sustained-release effect of encapsulated exosomes to the treatment of type 2 diabetes.
[0104] Modeling of type 2 diabetes: After the rats were fed with a high-fat diet for 30 days, they were continuously injected with streptozotocin (30 mg per kg body weight) for 5 days. After 3 days of observation, random blood sugar was measured, and blood sugar was measured for three consecutive days. If the daily blood sugar was >16.7 mM, an intraperitoneal glucose tolerance test (IPGTT) was performed, and the modeling was successful if the test was qualified.
[0105] IPGTT test: After the rats were fasted for 12 hours, their fasting blood sugar was measured, and 50% glucose solution was injected intraperitoneally (2 g per kg of body weight). The blood sugar levels were then tested at three time points: 40, 80 and 120 minutes, and the curves were drawn.
[0106] Exosome injection therapy: Functional enhanced exosomes (in PBS solution) at a concentration of 1 mg / mL were encapsulated in a sustained-release dynamic hydrogel, where the volume ratio of precursor solution: supplement solution: exosome solution was 6:1:3.
[0107] 500-700 μL of hydrogel was injected in situ on the pancreas of rats with type 2 diabetes model (the specific injection volume depends on the weight of the rat), so that the dose of exosomes in the rats is 1 mg of exosomes per kg of body weight. A total of five experimental groups were designed, including the normal group (healthy rats), the diabetic group (untreated type 2 diabetes model rats), the sustained-release dynamic hydrogel treatment group (type 2 diabetes model rats injected with sustained-release dynamic hydrogel), the exosome treatment group (type 2 diabetes model rats injected with functionally enhanced exosomes), and the sustained-release exosome treatment group (type 2 diabetes model rats injected with functionally enhanced exosomes encapsulated with sustained-release dynamic hydrogels). The normal group and the diabetic group were injected with the same volume of normal saline. Within two weeks after a single injection of exosomes, the blood glucose changes of the rats were monitored. The experimental results are as follows. Figure 8 shown. Figure 8 This is a summary of the average values of random blood sugar data measured at different time points for each rat in the five groups during the two-week treatment period. During the two-week period, the blood sugar of the group treated with sustained-release exosomes remained at a lower level, while in the exosome-treated group, a decrease in blood sugar was detected on the second day after injection. As the treatment cycle progressed, blood sugar rose to a hyperglycemic state. Fig. 9 and Fig.10 The IPGTT was tested on the seventh and 14th days respectively. This experiment further demonstrated that the sustained-release dynamic hydrogel in situ injection into the pancreas has a long-term therapeutic effect on type 2 diabetes, and can sustainably release functionally enhanced exosomes locally in the organ and control the blood sugar of type 2 diabetic rats within a two-week test period.
[0108] Example 5
[0109] This example investigates the regulatory effect of dynamic hydrogels on cell secretion of exosome proteins.
[0110] In order to verify the effect of the dynamic hydrogel of the present application in regulating cell behavior, the effects of bone marrow mesenchymal stem cells MSC encapsulated by dynamic hydrogels and two-dimensional culture and conventional hydrogel GelMA encapsulated bone marrow mesenchymal stem cells culture in the treatment of damaged β cells were investigated. The experimental method is as follows:
[0111] MSC and βcell co-culture experiment: A total of five groups were designed, including the normal β cell group (normal-βcell), the untreated group of damaged β cells treated with streptozotocin STZ (STZ-βcell), the MSC treatment group using two-dimensional culture (STZ-βcell+MSC), the MSC treatment group using GelMA encapsulation (STZ-βcell+MSC@GelMA), and the MSC treatment group using dynamic gel GelCD encapsulation (STZ-βcell+MSC@GelCD).
[0112] The co-culture experiment design of MSC and β cell is as follows: in GelMA hydrogel, the solid content of GelMA is 8%, and the formula of GelCD hydrogel is 8% gelatin + 10% modified CD. MSCs were encapsulated with GelMA and GelCD, respectively, with a density of 500,000 cells per 50μL gel. α-MEM complete medium (α-MEM + 20% fetal bovine serum + 1% streptomycin / penicillin + 1% L-glutamine) was used to culture them separately for two days to allow the mechanical properties of the dynamic gel to fully stimulate the MSCs. After the β cells were treated with STZ to become damaged β cells, the GelCD / GelMA encapsulating MSCs was co-cultured with damaged β cells using a 0.4μm pore transwell chamber. At the same time, 500,000 MSCs were loaded on a new transwell chamber to co-culture with damaged β cells (the MSCs here belong to the same batch as the MSCs encapsulated two days ago), and the MSC treatment group was set up. After three days of co-culture, subsequent CCK-8, qPCR and immunofluorescence staining experiments were performed.
[0113] In the CCK-8 test, under the same conditions, the MSC treatment group encapsulated by dynamic hydrogels was able to restore the activity of damaged β cells to 77% of normal cells, which was significantly higher than the other two treatment groups by 15% ( Fig.11As shown). In the subsequent qPCR experiment, for MSCs co-cultured with damaged β cells, MSC@GelMA and MSC@GelCD gene expression, the gene expression of Il-6, CNTF, TGF-β and adiponectin in MSC@GelCD was much higher than that in the other two groups, and these four genes have been reported in the literature to successfully treat type 2 diabetes. Therefore, it is believed that the paracrine function of MSCs stimulated by the unique mechanical properties of the dynamic gel is fully activated, so that more cell secretions with diabetes treatment effects can be secreted, which is difficult to achieve with conventional hydrogels. Therefore, the dynamic hydrogel of the present application has an outstanding role in regulating cell secretion.
[0114] This experiment further investigated the qPCR experiment of functionally enhanced exosomes obtained from dynamic hydrogels. The specific method was as follows:
[0115] 1. RNA extraction: 1 mL of Trizol reagent (Novozyme) was added to normal β cells, damaged β cells, control exosome treatment group, and enhanced exosome treatment group, respectively, and fully reacted on ice for 20 minutes; 200 μL of chloroform was added (pre-cooled on ice), inverted and mixed for about 60 times (pink white), and allowed to stand on ice until stratification (upper layer milky white, lower layer pink purple); 12000 rpm, 4 ° C centrifugation for 15 minutes, take the supernatant (about 500 μL), add an equal volume of isopropanol (pre-cooled on ice), gently inverted and mixed, and let stand on ice for 10 minutes to precipitate RNA; 12000 rpm, 4 ° C centrifugation for 10 minutes, a white precipitate will appear at this time, and the supernatant will be discarded in the clean bench; 900 μL 75% ethanol (prepared and used immediately, cooled on ice in advance), gently blow up the precipitate, centrifuge at 7500rpm, 4℃ for 5 minutes, discard the supernatant, and repeat twice; aspirate the ethanol, place the centrifuge tube in a clean bench and blow for 5 minutes, add 20μL of DEPC water, and place it in a 60℃ water bath for 10 minutes to dissolve the RNA precipitate.
[0116] 2. Reverse transcription: The RNA concentration was measured using the Thermo Fisher NanoDrop micro-spectrophotometer. Reverse transcription was performed using 2 μL of reverse transcriptase (Takara) and 500 ng of RNA per 10 μL system to obtain cDNA.
[0117] 3. qPCR experiment: In each reaction well, there is a 20 μL reaction system, and the volume of each component is shown in Table 3.
[0118] Table 3
[0119] Reagents volume Fast Taq Enzyme Mix (Takara) 10μL DEPC water (Biyuntian) 7.2μL cDNA 2μL qPCR Primer-F 0.4μL qPCR Primer-R 0.4μL
[0120] The reaction process is shown in Table 4.
[0121] Table 4
[0122] 95℃ 5 minutes 95℃ 15 seconds 60℃ 15 seconds 72℃ 15 seconds (return to 95°C for 15 seconds, amplify for 30 cycles and 40 cycles respectively) 4℃ ∞
[0123] Among them, the primers (Primer) detected by qPCR, the detection in this embodiment are: insulin, Pdx1, Nlrp3, Caspase3, Glut2, Glut4, among which Pdx1 is pancreatic duodenal homeobox 1, the activation of which can promote the expression of important genes of pancreatic β cells such as insulin, somatostatin, and glucokinase; Nlrp3 is a nucleotide binding oligomerization domain-like receptor protein, which belongs to the inflammasome; Caspase3 is caspase 3, a protease that can cause DNA cleavage and promote cell apoptosis; Glut2 / 4 are two kinds of glucose transport receptor proteins. Through experiments, it was found that the insulin and Pdx1 gene expressions in the enhanced exosome treatment group were the highest, proving that the enhanced exosomes can restore the ability of β cells to secrete insulin; Nlrp3 and Caspase3 gene expressions were the lowest, and the addition of surface enhanced exosomes improved the inflammatory microenvironment of damaged β cells; Glut2 / 4 gene expression was the highest, indicating that the enhanced exosomes also improved the function of β cells and promoted the restoration of cell vitality of β cells.
[0124] Proteomic analysis of exosomes
[0125] Sample preparation: Take out the frozen exosome sample, add liquid nitrogen, grind it thoroughly, add pre-cooled acetone containing 10% trichloroacetic acid in a ratio of 1:10, and precipitate at -20℃ for 1 hour. Centrifuge at 4℃, 15000g for 15 minutes, take the precipitate, add pre-cooled acetone, and precipitate at -20℃ for 1 hour. Repeat the above steps once. Centrifuge at 4℃, 15000g for 15 minutes, take the precipitate, and leave it open for about 5 minutes until the sample is dry. Add the dried precipitate to the phenol extraction solution and mix until the precipitate is evenly dispersed. Add an equal volume of phenol-Tris-hydrochloric acid (7.5) saturated solution and mix at 4℃ for 30 minutes. Centrifuge at 5000g for 30 minutes and collect the phenol upper layer. Add 5 times the volume of pre-cooled 0.1M ammonium acetate-methanol solution and precipitate at -20℃ for 1 hour. Centrifuge at 4℃, 10000g for 10 minutes and collect the precipitate. Then add 5 times the volume of pre-cooled methanol and mix gently. Centrifuge at 4℃, 10000g for 10 minutes and collect the precipitate. Repeat the steps twice with acetone instead of methanol to fully remove methanol. Centrifuge at 4°C, 10,000g for 10 minutes and collect the precipitate. Dissolve the dried powder in the sample lysis solution and fully dissolve the protein in a 30°C constant temperature water bath. Centrifuge the solution at 15,000g for 15 minutes at room temperature, take the supernatant, and centrifuge again to take the supernatant to fully remove insoluble impurities. The supernatant is the total protein solution of the tissue, and the protein concentration is measured and stored at -80°C after aliquoting for later use.
[0126] Total protein quantification: The sample concentration was determined by reference to the BCA method. 2+ Complexation and Cu 2+ Reduction to Cu + BCA and Cu + The complex combines to form a stable purple-blue complex with a high light absorption value at 562nm, which is proportional to the protein concentration, and the protein concentration can be determined based on this.
[0127] Sample detection: 20 μg of each sample was taken and separated by 12% SDS-PAGE electrophoresis. The separated gel was stained with Coomassie Brilliant Blue and scanned with Image Scanner in grayscale mode with an optical density of 300 dpi.
[0128] Protein reduction alkylation and enzymatic hydrolysis: The protein concentration in the supernatant was determined using a 500M triethylammonium bicarbonate (TEMB) kit, and then 100μg of each sample was transferred to a new test tube and adjusted to 100μL with 8M urea. 11μL of 1M dithiothreitol (DTT) was added and incubated at 37°C for 1 hour, and then the sample was added to a 10K ultrafiltration tube (Millipore) and centrifuged at 14000g for 10 minutes, and then 120μL of 55mM iodoacetamide was added and incubated at room temperature in the dark for 20 minutes. After three consecutive centrifugations with 100mM TEAB in the ultrafiltration tube to replace the urea system, 1:50 trypsin (Promega) was used for enzymatic hydrolysis overnight.
[0129] Liquid chromatography-mass spectrometry (LC-MS / MS) was used to measure the peptides: 30 μL of solvent (C: 0.1% formic acid in water; D: 0.1% formic acid in acetonitrile) was added to each sample to make a suspension, which was then separated by nano-LC and analyzed by online electrospray tandem mass spectrometry. The experiment was performed on an Easy-nLC 1000 system (Thermo Fisher Scientific, MA, USA), which was connected to a Q-Exactive mass spectrometer (Thermo Fisher Scientific, MA, USA) equipped with an online nano electrospray ion source. 10 μL of peptide samples were loaded onto a trapping column (Thermo Scientific Acclaim PepMap C18, 100 μm x 2 cm) at a flow rate of 10 μL / min, and then separated on an analytical column (Acclaim PepMap C18, 75 μm x 15 cm) with a linear gradient: 3% D to 32% D in 120 min. The column was equilibrated for 10 min under the initial conditions. The column flow rate was controlled at 300 nL / min and the electrospray voltage was 2 kV. The data results showed that the separation efficiency of most fractions was about 70%, no spray interruption occurred, and the gradient setting was relatively ideal.
[0130] According to proteomic analysis, 5003 proteins were identified under the standard of Peptide Threshold 1.0% FDR, 1 Unique Peptide, and the number of identified proteins was normal. The total number of spectra and mass accuracy were normal and reliable, and the spectrum identification rate was normal; the statistical significance evaluation of quantitative differential proteins was normal; differential protein analysis was performed by bioinformatics to analyze the protein families to which the number of up-regulated proteins and the number of down-regulated proteins belonged.
[0131] In this embodiment, bone marrow mesenchymal cells (MSC) are loaded in dynamic hydrogels, and cytoskeleton proteins are enriched using a cytoskeleton enrichment kit. Through proteomics sequencing, multiple differential proteins such as myotubularin-related protein 14 (MTMR14), fibromodulin, metalloproteinase inhibitor 2, mitochondrial fusion protein 1, type IV collagenase, FH1 / FH2 domain protein 1, and ATP-dependent RNA helicase are screened. By searching the KEGG functional database, it can be seen that MTMR14 is involved in triphosphate metabolism, and triphosphate is involved in the secretion of exosomes. By means of real-time quantitative PCR (qPCR), immunofluorescence staining, etc., it is further proved that dynamic hydrogels promote exosome secretion by regulating triphosphate metabolism. Therefore, the dynamic hydrogel of the present application can regulate the secretion of exosomes by cells through its rich mechanical properties and mechanical adaptability, which is a non-engineered natural regulatory means.
[0132] The above embodiments are only used to illustrate the technical solution of the present invention rather than to limit the protection scope of the present invention. Although the present invention has been described in detail with reference to the preferred embodiments, those skilled in the art should understand that the technical solution of the present invention can be modified or replaced by equivalents without departing from the essence and scope of the technical solution of the present invention.
Claims
1. A method for preparing exosomes, comprising the following steps: 1) adding gelatin, cyclodextrin modified with acrylic groups and a photoinitiator into a buffer solution to prepare a precursor solution; mixing cells and the precursor solution, and photoinitiating cross-linking to form a dynamic hydrogel encapsulating the cells; 2) placing the dynamic hydrogel in a culture medium for culture, collecting the culture medium, and separating and purifying to obtain exosomes; in, The mass volume percentage of gelatin in the precursor solution is 5-15%, the mass volume percentage of cyclodextrin modified by acrylic acid group is 5-15%, and the mass volume percentage of photoinitiator is 0.01-0.5%.
2. The method according to claim 1, characterized in that The cell is a stem cell, and the exosomes obtained from the cell are used for one of the following a)-b): a) preparing a pharmaceutical composition for treating diabetes; b) preparing a preparation or composition that has the effects of lowering blood sugar, repairing insulin cells, increasing insulin expression, and improving insulin resistance.
3. Application of dynamic hydrogel in the preparation of exosomes, wherein the dynamic hydrogel comprises a dynamic cross-linked network formed by gelatin and cyclodextrin modified with acrylic groups through host-guest interaction and covalent cross-linking, and the covalent cross-linking is initiated by light through the modified cyclodextrin.
4. The use as claimed in claim 3, further comprising using the dynamic hydrogel to deliver the exosomes, wherein the dynamic hydrogel is connected to a polypeptide that can bind to the exosomes; preferably, the polypeptide is connected to the dynamic hydrogel via N-hydroxysuccinimide modified with an acrylic group.
5. The use according to claim 4, characterized in that The polypeptide is one or more of CP05 and its derivative peptides, CP06 and its derivative peptides, CP07 peptide and its derivative peptides, and integrin-related binding peptides, and preferably a glycine G is added before the N-terminus of the polypeptide peptide segment.
6. A method for preparing an exosome delivery system, comprising: i) mixing gelatin and cyclodextrin modified with acrylic groups in a buffer solution, adding a photoinitiator, and preparing a precursor solution; ii) premixing acrylic group-modified N-hydroxysuccinimide with a polypeptide as a supplementing solution, then adding the supplementing solution to the exosomes to obtain an exosome mixed solution, and then adding the mixed solution to the precursor solution to form a sustained-release dynamic hydrogel as an exosome delivery system by light-induced cross-linking; Wherein, the polypeptide is a polypeptide that can bind to the exosomes.
7. The method according to claim 6, characterized in that The polypeptide is one or more of CP05 and its derivative peptides, CP06 and its derivative peptides, CP07 peptide and its derivative peptides, and integrin-related binding peptides, and preferably a glycine G is added before the N-terminus of the polypeptide peptide segment.
8. The method according to claim 6 or 7, characterized in that By adjusting the ratio of supplemental fluid to exosomes, the release cycle of the exosome delivery can be regulated.
9. Use of a reagent in the preparation and delivery of exosomes, characterized in that: The reagent includes a precursor solution, wherein the precursor solution includes gelatin, cyclodextrin modified with acrylic groups, and a photoinitiator. After the precursor solution encapsulates cells, light-induced cross-linking forms a dynamic hydrogel, and after adding cell culture medium for culture, exosomes are separated and purified from the cell culture medium; after obtaining the exosomes, the precursor solution is added again, and light-induced cross-linking forms a dynamic hydrogel for exosome delivery; The mass volume percentage of gelatin in the precursor solution is 5-15%, the mass volume percentage of cyclodextrin modified with acrylic acid groups is 5-15%, and the mass volume percentage of the photoinitiator is 0.01-0.5%.
10. An exosome kit, characterized in that: The kit comprises a precursor solution and a replenisher, wherein the precursor solution comprises gelatin, cyclodextrin modified with an acrylic group, and a photoinitiator, and the replenisher comprises a polypeptide that can bind to exosomes and N-hydroxysuccinimide modified with an acrylic group; wherein the mass volume percentage of gelatin in the precursor solution is 5-15%, the mass volume percentage of cyclodextrin modified with an acrylic group is 5-15%, and the mass volume percentage of the photoinitiator is 0.01-0.5%.
11. The kit according to claim 10, characterized in that The polypeptide that can bind to exosomes is one or more of CP05 and its derivative peptides, CP06 and its derivative peptides, CP07 peptide and its derivative peptides, and integrin-related binding peptides; preferably, a glycine G is added before the N-terminus of the polypeptide peptide segment.
12. The kit according to claim 10 or 11, characterized in that By adjusting the ratio of supplemental fluid to exosomes, the release cycle of the exosome delivery can be regulated.
Citation Information
Patent Citations
Polypeptide hydrogel with slow-release exosomes and preparation method and application thereof
CN110229214A
Host-guest supramolecular hydrogel induced by visible light in situ polymerization and preparation method and application thereof
CN112538170A
Application of dynamic cross-linked hydrogel in cell culture
CN115558634A
Exosome production method
WO2024048643A1
Cited By
DHEA polypeptide, sustained-release hydrogel, coated exosome delivery preparation and application
CN119708137A
Exosome delivery system and application thereof in treatment of temporomandibular arthritis
CN120501765A
